Ísrael - enska - Ministry of Health

kamada ltd - heparin as sodium 100 iu/ml - solution for injection - heparin - to maintain patency of an indwelling intravenous catheter designed for intermittent injection or blood sampling.

Bandaríkin - enska - NLM (National Library of Medicine)

safecor health, llc - heparin sodium (unii: zz45ab24ca) (heparin - unii:t2410km04a) - heparin 5000 [usp'u] in 1 ml - heparin sodium injection, usp is indicated for: anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension; low-dose regimen for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease (see dosage and administration ); prophylaxis and treatment of pulmonary embolism; atrial fibrillation with embolization; treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); prevention of clotting in arterial and cardiac surgery; prophylaxis and treatment of peripheral arterial embolism. heparin may also be employed as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures. heparin sodium should not be used in patients with the following conditions: severe thrombocytopenia; when suitable blood coagulation tests, e.g., the whole b

Bandaríkin - enska - NLM (National Library of Medicine)

sandoz inc - heparin sodium (unii: zz45ab24ca) (heparin - unii:t2410km04a) - heparin 5000 [usp'u] in 1 ml - heparin sodium injection is indicated for: the use of heparin sodium injection is contraindicated in patients with the following conditions: risk summary there are no available data on heparin sodium injection use in pregnant women to inform a drug- associated risk of major birth defects and miscarriage. in published reports, heparin exposure during pregnancy did not show evidence of an increased risk of adverse maternal or fetal outcomes in humans. no teratogenicity, but early embryo-fetal death was observed in animal reproduction studies with administration of heparin sodium to pregnant rats and rabbits during organogenesis at doses approximately 10 times the maximum recommended human dose (mrhd) of 45,000 units/ day (see data) . consider the benefits and risks of heparin sodium injection for the mother and possible risks to the fetus when prescribing heparin sodium injection to a pregnant woman. if available, preservative-free heparin sodium injection is recommended when heparin therapy is needed during pr

Bandaríkin - enska - NLM (National Library of Medicine)

fresenius kabi usa, llc - heparin sodium (unii: zz45ab24ca) (heparin - unii:t2410km04a) - heparin 5000 [usp'u] in 1 ml - heparin sodium injection is indicated for: - prophylaxis and treatment of venous thrombosis and pulmonary embolism; - prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; - atrial fibrillation with embolization; - treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); - prevention of clotting in arterial and cardiac surgery; - prophylaxis and treatment of peripheral arterial embolism. - anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures. the use of heparin sodium injection is contraindicated in patients with the following conditions: - history of heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis [see warnings and precautions (5.3)] ; - known hypersensitivity to heparin or pork products (e.g., anaphylactoid reactions) [see adverse reactions

Bandaríkin - enska - NLM (National Library of Medicine)

fresenius kabi usa, llc - heparin sodium (unii: zz45ab24ca) (heparin - unii:t2410km04a) - heparin 5000 [usp'u] in 100 ml - heparin sodium is indicated for: - prophylaxis and treatment of venous thromboembolism and pulmonary embolism; - atrial fibrillation with embolization; - treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); - prevention of clotting in arterial and cardiac surgery; - prophylaxis and treatment of peripheral arterial embolism; - anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures. the use of heparin sodium in 0.45% sodium chloride injection or heparin sodium in 5% dextrose injection is contraindicated in patients with the following conditions: - history of heparin-induced thrombocytopenia (hit) and heparin-induced thrombocytopenia and thrombosis (hitt) [see warnings and precautions (5.3)] - known hypersensitivity to heparin or pork products (e.g., anaphylactoid reactions) [see adverse reactions (6.1)] - in whom suitable blood coagulation tests — e.g., the whole blood clotting time, partial thro

Bandaríkin - enska - NLM (National Library of Medicine)

sagent pharmaceticals - heparin sodium (unii: zz45ab24ca) (heparin - unii:t2410km04a) - heparin 1000 [usp'u] in 1 ml - heparin sodium injection is indicated for: - prophylaxis and treatment of venous thrombosis and pulmonary embolism - prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease - atrial fibrillation with embolization - treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation) - prevention of clotting in arterial and cardiac surgery - prophylaxis and treatment of peripheral arterial embolism - anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures the use of heparin sodium is contraindicated in patients with the following conditions: - history of heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis [see warnings and precautions (5.3)] - known hypersensitivity to heparin or pork products (e.g., anaphylactoid reactions) [see adverse reactions (6.1)] - in whom su

Spánn - spænska - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

hospira invicta s.a. - heparina sodica - soluciÓn inyectable - 1.000 ui/ml inyectable 5 ml - heparina sodica 1000 ui - heparina

Spánn - spænska - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

hospira invicta s.a. - heparina sodica - soluciÓn inyectable - 5.000 ui/ml inyectable 5 ml - heparina sodica 5000 ui - heparina

Portúgal - portúgalska - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

panpharma s.a. - heparina sódica - solução injetável - 5000 u.i./ml - heparina sódica 5000 u.i. - heparin - n/a - duração do tratamento: longa duração

Portúgal - portúgalska - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

panpharma s.a. - heparina sódica - solução injetável - 5000 u.i./ml - heparina sódica 5000 u.i. - heparin - n/a - duração do tratamento: longa duração